{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"Objective response rate (ORR) based on International Myeloma Working Group (IMWG) uniform response criteria of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR)","groups":[{"description":"50 mg BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.","id":"OG000","title":"BION-1301 50 mg Q2W"},{"description":"150 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG001","title":"BION-1301 150 mg Q2W"},{"description":"450 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG002","title":"BION-1301 450 mg Q2W"},{"description":"1350 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG003","title":"BION-1301 1350 mg Q2W"},{"description":"2700 mg BION-1301 will be administered once every 2 weeks as an IV infusion.","id":"OG004","title":"BION-1301 2700 mg Q2W"},{"description":"1350 mg BION-1301 will be administered as an IV infusion once per week for up to 8 weeks, followed by dosing once every 2 weeks.","id":"OG005","title":"BION-1301 1350 mg QW*8W->Q2W"}],"populationDescription":"Study was terminated early and Phase 2 was not enrolled. Objective response rate was not assessed.","reportingStatus":"POSTED","timeFrame":"Approximately 30 months","title":"Response Rate (Phase 2)","type":"PRIMARY"}